NEJM· @NEJM · X·· 6 天前精选AI 评分80
AI 导读
NEJM发布III期RAINIER AIS-D08试验结果,在IgA肾病患者中,BAFF与APRIL双抑制剂povetacicept较安慰剂显著降低蛋白尿。完整结果与研究摘要见 https://nej.md/3VWcGh6。
推荐理由
III期RAINIER试验显示povetacicept在IgA肾病患者中降蛋白尿优于安慰剂,读者可据此了解该双靶点抑制剂的疗效证据。
正文
Among participants with IgA nephropathy, povetacicept, a dual inhibitor of B-cell activating factor and a proliferation-inducing ligand, led to a significantly greater reduction in proteinuria than placebo. Full phase 3 RAINIER AIS-D08 trial results and Research Summary: https://nej.md/3VWcGh6
来源:NEJM · x.com